Results Will Add to Research and be Published"Braxia’s Chief Medical and Scientific Officer, and CRTCE Medical Director, Dr. Josh Rosenblat, commented, “As we provide ketamine treatments for this population, we are also carefully collecting outcome data to help refine treatment protocols and quantitatively determine the real-world effectiveness of ketamine and related treatments in this population. We are specifically tracking symptoms of depression, anxiety, suicidality and PTSD. We have seen some promising benefits for many veterans that have received this novel treatment in our clinic and plan to publish our findings in the coming months.”